BioXcel Therapeutics Receives FDA Orphan Drug Designation for BXCL701 for the Treatment of Acute Myeloid Leukemia (AML)

BioXcel Therapeutics Announces Award of Grant by U.S. Department of Defense’s (“DoD”) Congressionally Directed Medical Research Programs (“CDMRP”) for Development of BXCL501

H.C. Wainwright Annual Global Investment Conference

Sep 10, 2019 • 8:45am EDT

NewsMakers in the Biotech Industry

Sep 6, 2019 • 2:50pm EDT